News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI Yael L. Maxwell November 13, 2017